Haloperidol-Ratiopharm (Haloperidol)

Haloperidol‑Ratiopharm is prescribed for several psychiatric disorders where dopamine blockade is therapeutic.

• Management of schizophrenia, including maintenance therapy.
• Treatment of acute psychotic episodes.
• Control of symptoms in Tourette syndrome.
• Adjunctive therapy for manic episodes in bipolar disorder.
• Short‑term relief of severe agitation or aggression.
• Use in combination with other agents for refractory psychosis.

Side effects of haloperidol can vary in frequency and severity.

Common

• Extrapyramidal symptoms such as tremor, rigidity, or akathisia.
• Drowsiness or sedation.
• Dry mouth and increased salivation.
• Constipation or gastrointestinal discomfort.
• Weight gain or appetite changes.
• Blurred vision.

Serious

• Neuroleptic malignant syndrome.
• Tardive dyskinesia with prolonged use.
• Significant cardiac arrhythmias (QT prolongation).
• Severe hypotension or orthostatic dizziness.
• Hyperprolactinemia leading to hormonal disturbances.
• Hepatic enzyme elevation.

Before initiating Haloperidol‑Ratiopharm, clinicians should evaluate several safety considerations.

• Assess cardiovascular history, especially for QT interval prolongation risk.
• Monitor for signs of extrapyramidal reactions, especially in elderly patients.
• Use caution in patients with a history of seizures or neurological disorders.
• Evaluate liver and kidney function periodically during therapy.
• Discuss potential hormonal effects, such as menstrual changes or gynecomastia.
• Avoid abrupt discontinuation to reduce withdrawal or rebound psychosis.
• Consider pregnancy and lactation status; use only if benefits outweigh risks.

Haloperidol can interact with a range of medications, influencing its efficacy and safety profile.

Avoid

• Other dopamine antagonists or antipsychotics that may increase extrapyramidal risk.
• Medications that prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics).
• Strong CYP3A4 inhibitors such as ketoconazole or clarithromycin.

Use with caution

• CYP3A4 inducers like rifampin or carbamazepine, which may reduce haloperidol levels.
• CNS depressants (e.g., benzodiazepines, opioids) that can enhance sedation.
• Anticholinergic agents that may mask extrapyramidal symptoms.
• Antihypertensive drugs, as haloperidol may cause orthostatic hypotension.